Renalytix Plc

Renalytix plc's next confirmed earnings release is scheduled for November 3, 2026.

As of December 31, 2024, Renalytix plc has 215.89M shares outstanding.

As of December 31, 2024, Renalytix plc maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -140.64, reflecting losses generated across the asset base. The company generates approximately 44,130.23 in revenue per employee across its workforce of 53.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.10 indicates how many times Renalytix plc sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on August 10, 2026, Renalytix plc's stock has declined approximately 27.22% over the past 52 weeks.

Over the twelve months ended December 31, 2024, Renalytix plc generated 2.37M in revenue and converted that into -23.43M in net income, yielding earnings per share of -0.15. EBITDA reached -19.61M, while operating income came in at -19.15M.

As of December 31, 2024, Renalytix plc holds 9.63M in cash and equivalents against 8.21M in total debt, resulting in a net debt position of -1.00M. Total book value stands at -1.37M, with working capital of 6.59M providing operational flexibility.

Renalytix plc produced -23.10M in operating cash flow over the twelve months ended December 31, 2024. After subtracting -1,000.00 in capital expenditures, free cash flow totaled -23.10M - equivalent to -0.15 per share.

Over the twelve months ended December 31, 2024, Renalytix plc posted a gross margin of 19.73, reflecting its pricing power and cost economics. The operating margin of -807.29 and net profit margin of -987.65 provide insight into operational efficiency.